Osiris gains $50M

Baltimore-based Osiris Therapeutics has pocketed $50 million from a Swiss investment firm. That's more than twice the $20 million the biotech had hoped to raise in the round. Zurich-based Friedli Corporate Finance, which is owned by Osiris' chairman of the board, led the round. Osiris has been hot on the trail of a new adult stem cell treatment to regenerate diseased or damaged tissue. It expects to have its first commercial offering in 2006.

- read this story from the Baltimore Sun

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.